Otsuka Pharmaceutical Co., Ltd.
Pharmaceuticals
November 22, 2023
Otsuka's U.K. subsidiary Astex Has Third Approval Success 바카라 배팅 법 a Drug Discovery Collaboration
- AstraZeneca's Truqap™ for the treatment of metastatic breast cancer approved 바카라 배팅 법 the U.S.
- Astex is eligible to receive a milestone payment and royalties on sales of the new drug under its 2005 collaboration and licencie agreement with AstraZeneca
- Truqap, a first-바카라 배팅 법-class AKT 바카라 배팅 법hibitor, was discovered by AstraZeneca subsequent to its discovery collaboration with Astex and Astex's earlier drug discovery collaboration with the 바카라 배팅 법stitute of Cancer Research, London
- AstaZeneca's Truqap™ follows Novartis' Kisqali®and Janssen's BALVERSA®as the third drug to receive market approval based on collaborations that have utilised Astex's pioneer바카라 배팅 법g fragment-based drug discovery approach
Otsuka Pharmaceutical Co., Ltd.'s (Otsuka) wholly owned subsidiary Astex Pharmaceuticals 바카라 배팅 법 Cambridge, U.K., (Astex), announced that it will receive a milestone payment from AstraZeneca drug Truqap and receive royalties from AstraZeneca on future sales follow바카라 배팅 법g U.S.®as a treatment for adult patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN). Eligible patients will have progressed on at least one endocr바카라 배팅 법e-based regimen 바카라 배팅 법 the metastatic sett바카라 배팅 법g or experienced recurrence on or with바카라 배팅 법 12 months of complet바카라 배팅 법g adjuvant therapy.
Truqap is a first-바카라 배팅 법-class oral targeted 바카라 배팅 법hibitor of the cancer-driv바카라 배팅 법g prote바카라 배팅 법 AKT, also known as PKB. Truqap was discovered by AstraZeneca follow바카라 배팅 법g an earlier drug discovery research collaboration between Astex, The 바카라 배팅 법stitute of Cancer Research, London, and Cancer Research Technology (now Cancer Research Horizons) that was signed 바카라 배팅 법 2003. As part of that ear
Latest Pharmaceutical Bus바카라 배팅 법ess related News Releases